BlackRock’s Elicio Therapeutics ELTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3M Buy
766,005
+715,408
+1,414% +$7.18M ﹤0.01% 4058
2026
Q1
$541K Buy
50,597
+5,418
+12% +$52.3K ﹤0.01% 4509
2025
Q4
$360K Buy
45,179
+984
+2% +$8.93K ﹤0.01% 4573
2025
Q3
$483K Buy
44,195
+638
+1% +$6.46K ﹤0.01% 4463
2025
Q2
$336K Buy
43,557
+4,234
+11% +$26.3K ﹤0.01% 4538
2025
Q1
$242K Buy
39,323
+19,512
+98% +$151K ﹤0.01% 4569
2024
Q4
$101K Buy
19,811
+118
+0.6% +$581 ﹤0.01% 4788
2024
Q3
$99.1K Buy
19,693
+708
+4% +$3.14K ﹤0.01% 4670
2024
Q2
$78K Buy
18,985
+18,068
+1,970% +$153K ﹤0.01% 4759
2024
Q1
$6.97K Hold
917
﹤0.01% 5116
2023
Q4
$7.65K Buy
+917
New +$5.98K ﹤0.01% 5165
2023
Q2
Sell
-5,705
Closed -$33.1K 5529
2023
Q1
$33.1K Buy
5,705
+178
+3% +$1.19K ﹤0.01% 5184
2022
Q4
$44.9K Buy
5,527
+119
+2% +$1.08K ﹤0.01% 5255
2022
Q3
$50K Sell
5,408
-149
-3% -$1.56K ﹤0.01% 5350
2022
Q2
$63K Sell
5,557
-95,309
-94% -$1.52M ﹤0.01% 5367
2022
Q1
$2.14M Sell
100,866
-1,367
-1% -$30.9K ﹤0.01% 4360
2021
Q4
$2.96M Buy
102,233
+446
+0.4% +$22.6K ﹤0.01% 4238
2021
Q3
$9.95M Buy
101,787
+73,683
+262% +$7.96M ﹤0.01% 3672
2021
Q2
$3.66M Sell
28,104
-3,267
-10% -$471K ﹤0.01% 4010
2021
Q1
$5.67M Buy
+31,371
New +$6.05M ﹤0.01% 3886

Other funds holding ELTX

BlackRock's ELTX Position: Q2 2026 in Review

BlackRock increased its Elicio Therapeutics (ELTX) stake by 1,414% in Q2 2026, buying an estimated $7.18M and bringing the position to 766,005 shares worth $3M. The position accounts for ﹤0.01% of the portfolio, ranked #4058.

BlackRock first reported a position in ELTX in Q1 2021 and has held it in 20 quarters since. The position peaked at $9.95M in Q3 2021. 46 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • BlackRock held 766,005 shares of Elicio Therapeutics worth $3M as of Q2 2026.
  • BlackRock bought 715,408 Elicio Therapeutics shares in Q2 2026, an estimated $7.18M.
  • Elicio Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4058 holding.
  • BlackRock first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • BlackRock's Elicio Therapeutics position peaked at $9.95M in Q3 2021.
  • 46 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.